首页 | 本学科首页   官方微博 | 高级检索  
检索        

活血化瘀方药血塞通胶囊调控CD117+造血干细胞“生新血”的实验研究
引用本文:张宝霞,张金生,杜梅梅,张阳阳,朱慧芳.活血化瘀方药血塞通胶囊调控CD117+造血干细胞“生新血”的实验研究[J].中国中药杂志,2014,39(12):2341-2344.
作者姓名:张宝霞  张金生  杜梅梅  张阳阳  朱慧芳
作者单位:河南中医学院 第一附属医院, 河南 郑州 450008;河南中医学院 第三附属医院, 河南 郑州 450000;河南中医学院 第三附属医院, 河南 郑州 450000;河南中医学院 第三附属医院, 河南 郑州 450000;河南中医学院 第三附属医院, 河南 郑州 450000
基金项目:2010年河南省高校杰出科研人才创新工程-科技创新杰出青年项目(104100510010)
摘    要:目的: 探讨活血化瘀方药血塞通胶囊调控造血干细胞(hemopoietic stem cell,HSC)“生新血”的机制。 方法: 参照改良Zea-Longa法建立大鼠大脑中动脉脑缺血再灌注损伤模型(middle cerebral artery occlusion,MCAO)。随机分为正常组、模型组、血塞通高、中、低剂量组;各组再随机按1,3,7,14,28 d时间点分为亚组。血塞通胶囊配置成20,40,60 g·L-1灌胃。正常组和模型组生理盐水灌胃,每天1次,直到实验结束。ELISA法检测不同时间点血液和骨髓中干细胞因子(stem cell factor,SCF)表达情况;流式细胞仪检测外周血和骨髓中CD117的变化。 结果: 模型组外周血和骨髓中CD117+HSC和SCF从1 d开始升高,14 d到高峰,其后逐渐降低。血塞通高、中剂量组外周血和骨髓中CD117+HSC和SCF在同一时间点上升的趋势明显优于模型组(P<0.05)。 结论: 活血化瘀生新层面之“生新血”是通过调控CD117+HSC数量变化实现生新血目的。

关 键 词:活血化瘀  血塞通胶囊  造血干细胞  脑梗死
收稿时间:2013/12/22 0:00:00

Research about formulas for activating blood and resolving stasis Xuesaitong capsule regulate CD117+ hemopoietic stem cell to produce new blood
ZHANG Bao-xi,ZHANG Jin-sheng,DU Mei-mei,ZHANG Yang-yang and ZHU Hui-fang.Research about formulas for activating blood and resolving stasis Xuesaitong capsule regulate CD117+ hemopoietic stem cell to produce new blood[J].China Journal of Chinese Materia Medica,2014,39(12):2341-2344.
Authors:ZHANG Bao-xi  ZHANG Jin-sheng  DU Mei-mei  ZHANG Yang-yang and ZHU Hui-fang
Institution:First Affiliated Hospital of Henan College of Traditional Chinese Medicine, Zhengzhou 450008, China;Third Affiliated Hospital of Henan College of Traditional Chinese Medicine, Zhengzhou 450000, China;Third Affiliated Hospital of Henan College of Traditional Chinese Medicine, Zhengzhou 450000, China;Third Affiliated Hospital of Henan College of Traditional Chinese Medicine, Zhengzhou 450000, China;Third Affiliated Hospital of Henan College of Traditional Chinese Medicine, Zhengzhou 450000, China
Abstract:Objective: To investigate the mechanism that the formulas for activating blood and resolving stasis can regulate hemopoietic stem cell to produce new blood. Method: Rats were established animal model of acute cerebral infarction by referencing Olivette'method. They were randomly divided into model group, the group of the high,middle, low dose of the formulas for activating blood and resolving stasis. Each group and then wasrandomly divided into subgroups by 1, 3, 7, 14, 28 d. Xuesaitong capsule was formulated into 20, 40, 60 g·L-1 with normal saline.The rats were given gavage drugs once a day until the experient ended, and the model group was administrated by intragastrical perfusion of normal saline. ELISA was used to detect the expression of SCF in peripheral blood and bone marrow among different groups at different time points. Flow cytometry was used to observe the changes of CD117 in blood and bone marrow. Result: The CD117+HSC and SCF concentration in peripheral blood and bone marrow of model group were increasing during 1-14 d,there was a peak on the 14th day, then the expression was reducing. CD117+HSC and SCF concentration rising trend in the group of the high, middle dose of the formulas for activating blood and resolving stasis was preceded model group(P<0.05). Conclusion: Activating blood and resolving stasis can regulate hemopoietic stem cell to produce new blood, and it is through the regulation of CD117+HSC number to achieve the purpose.
Keywords:activating blood and resolving stasis  Xuesaitong capsule  hemopoietic stem cell  cerebral infarction
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号